[HTML][HTML] Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)
JP Leonard, SH Jung, J Johnson… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
JP Leonard, SH Jung, J Johnson, BN Pitcher, NL Bartlett, KA Blum, M Czuczman…
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.govRandomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With
Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal
List J Clin Oncol PMC4622102 Other Formats PDF (150K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal
List J Clin Oncol PMC4622102 Other Formats PDF (150K) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
Abstract
Purpose
Lenalidomide and rituximab (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed in randomized studies.
ncbi.nlm.nih.gov